Merck and Moderna's cancer vaccine is customized for each patient's tumor

Merck and Moderna have developed a personalized cancer vaccine that is tailored to the genetic mutations of an individual patient's tumor and used in combination with Merck's Keytruda. The therapy showed positive Phase 3 trial results and received FDA Breakthrough Therapy designation, offering a new targeted treatment option particularly in melanoma patients at high risk of recurrence.

This Wire brief sits within Fusion42's coverage of Biotech, and 6 sources have reported it between 19 Aug 2026 and 31 Aug 2026.